Show simple item record

dc.contributor.authorFalade, Catherine Oen_US
dc.contributor.authorYusuf, Bidemi Oen_US
dc.contributor.authorFadero, Francis Fen_US
dc.contributor.authorMokuolu, Olugbenga Aen_US
dc.contributor.authorHamer, Davidson Hen_US
dc.contributor.authorSalako, Lateef Aen_US
dc.date.accessioned2012-01-09T20:58:39Z
dc.date.available2012-01-09T20:58:39Z
dc.date.copyright2007en_US
dc.date.issued2007-7-6en_US
dc.identifier.citationFalade, Catherine O, Bidemi O Yusuf, Francis F Fadero, Olugbenga A Mokuolu, Davidson H Hamer, Lateef A Salako. "Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria" Malaria Journal 6:88. (2007)en_US
dc.identifier.issn1475-2875en_US
dc.identifier.urihttp://hdl.handle.net/2144/2946
dc.description.abstractBACKGROUND Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas. This study sets out to evaluate the effectiveness of IPT-SP in the prevention of maternal and placental malaria in parturient mothers in Ibadan, Nigeria, where the risk of malaria is present all year round. METHOD During a larger study evaluating the epidemiology of congenital malaria, the effect of malaria prophylaxis was examined in 983 parturient mothers. Five hundred and ninety eight mothers (60.8%) received IPT-SP, 214 (21.8%) received pyrimethamine (PYR) and 171 (17.4%) did not take any chemoprophylactic agent (NC). RESULTS The prevalence of maternal parasitaemia in the IPT-SP, PYR and NC groups was 10.4%, 15.9% and 17% respectively (p = 0.021). The prevalence of placental parasitaemia was 10.5% in the IPT-SP, 16.8% PYR and 17% NC groups, respectively (p = 0.015). The prevalence of maternal anaemia (haematocrit <30%) was 5.7% vs. 8.9% vs. 13.4% among the IPT-SP, PYR and NC groups respectively (p <0.0001) while that of pre-term delivery (GA <37 weeks) was 10.5%, 19.2% and 25.3% among IPT-SP, PYR and NC groups respectively (p <0.0001). Babies born to mothers in the IPT-SP, PYR and NC groups had mean birth weights of 3204 ± 487.16, 3075 ± 513.24 and 3074 ± 505.92 respectively (ρ <0.0001). There was a trend towards a lower proportion of low birth weight babies in the IPT-SP group (p = 0.095). CONCLUSION IPT-SP is effective in preventing maternal and placental malaria as well as improving pregnancy outcomes among parturient women in Ibadan, Nigeria. The implementation of the recently adopted IPT-SP strategy should be pursued with vigour as it holds great promise for reducing the burden of malaria in pregnancy in Nigeria.en_US
dc.description.sponsorshipCooperative Agreement between Boston University and the Office of Health and Nutrition of the United States Agency for International Developmenten_US
dc.language.isoenen_US
dc.publisherBioMed Centralen_US
dc.rightsCopyright 2007 Falade et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/2.0en_US
dc.titleIntermittent Preventive Treatment with Sulphadoxine-Pyrimethamine Is Effective in Preventing Maternal and Placental Malaria in Ibadan, South-Western Nigeriaen_US
dc.typearticleen_US
dc.identifier.doi10.1186/1475-2875-6-88en_US
dc.identifier.pubmedid17617910en_US
dc.identifier.pmcid1941736en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Copyright 2007 Falade et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Except where otherwise noted, this item's license is described as Copyright 2007 Falade et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.